Literature DB >> 9064287

Monoclonal antibodies directed against the amino-terminal domain of human TBP cross-react with TBP from other species.

S M Ruppert1, V McCulloch, M Meyer, C Bautista, M Falkowski, H G Stunnenberg, N Hernandez.   

Abstract

The TATA box-binding protein (TBP) is a key transcription factor required for transcription by all three eukaryotic RNA polymerases. It consists of a conserved carboxy-terminal DNA binding domain and a highly divergent amino terminal domain. TBP and different sets of TBP-associated factors (TAFs) constitute at least four multisubunit complexes referred to as SL1, TFIID, TFIIIB, and SNAPC. SL1, TFIID, and TFIIIB are required for transcription by RNA polymerases I, II, and III, respectively, while the SNAP complex is involved in transcription of the small nuclear RNA (snRNA) genes by RNA polymerases II and III. TBP also associates with a number of basal transcription factors such as TFIIA and TFIIB, and with several regulatory factors such as VP16, E1A, and p53. Here we describe the characterization of a panel of monoclonal antibodies (MAbs) directed against the amino-terminal domain of human TBP. These MAbs recognize different TBP epitopes, some of which have been precisely defined. Different MAbs recognize different TBP-containing complexes and several of them crossreact with TBP from other species. These antibodies can be used to purify TBP-containing complexes in a functional form and should be useful to identify new protein-protein interactions involving TBP.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9064287     DOI: 10.1089/hyb.1996.15.55

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  22 in total

1.  Cascade of distinct histone modifications during collagenase gene activation.

Authors:  Joost H A Martens; Matty Verlaan; Eric Kalkhoven; Alt Zantema
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

2.  Transcription of the Schizosaccharomyces pombe U2 gene in vivo and in vitro is directed by two essential promoter elements.

Authors:  D Zhou; S M Lobo-Ruppert
Journal:  Nucleic Acids Res       Date:  2001-05-15       Impact factor: 16.971

3.  The retinoblastoma tumor suppressor protein targets distinct general transcription factors to regulate RNA polymerase III gene expression.

Authors:  H A Hirsch; L Gu; R W Henry
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

4.  Peroxisome proliferator-activated receptor subtype- and cell-type-specific activation of genomic target genes upon adenoviral transgene delivery.

Authors:  Ronni Nielsen; Lars Grøntved; Hendrik G Stunnenberg; Susanne Mandrup
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

5.  p300 is involved in formation of the TBP-TFIIA-containing basal transcription complex, TAC.

Authors:  Dimitra J Mitsiou; Hendrik G Stunnenberg
Journal:  EMBO J       Date:  2003-09-01       Impact factor: 11.598

6.  p300/CREB binding protein-related protein p270 is a component of mammalian SWI/SNF complexes.

Authors:  P B Dallas; I W Cheney; D W Liao; V Bowrin; W Byam; S Pacchione; R Kobayashi; P Yaciuk; E Moran
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

7.  Characterization of monoclonal antibodies raised against p300: both p300 and CBP are present in intracellular TBP complexes.

Authors:  P B Dallas; P Yaciuk; E Moran
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

8.  Regulation of human RNA polymerase III transcription by DNMT1 and DNMT3a DNA methyltransferases.

Authors:  Tharakeswari Selvakumar; Alison Gjidoda; Stacy L Hovde; R William Henry
Journal:  J Biol Chem       Date:  2012-01-04       Impact factor: 5.157

9.  Distinct mechanisms for repression of RNA polymerase III transcription by the retinoblastoma tumor suppressor protein.

Authors:  Heather A Hirsch; Gauri W Jawdekar; Kang-Ae Lee; Liping Gu; R William Henry
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

10.  TBP2 is a substitute for TBP in Xenopus oocyte transcription.

Authors:  Waseem Akhtar; Gert Jan C Veenstra
Journal:  BMC Biol       Date:  2009-08-03       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.